Jump Financial LLC Has $988,000 Stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Jump Financial LLC reduced its holdings in Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) by 63.6% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 8,121 shares of the medical equipment provider's stock after selling 14,172 shares during the period. Jump Financial LLC's holdings in Zimmer Biomet were worth $988,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also made changes to their positions in ZBH. Schechter Investment Advisors LLC raised its holdings in shares of Zimmer Biomet by 21.6% during the third quarter. Schechter Investment Advisors LLC now owns 4,241 shares of the medical equipment provider's stock valued at $476,000 after acquiring an additional 752 shares during the last quarter. Atria Wealth Solutions Inc. lifted its holdings in Zimmer Biomet by 5.9% in the 3rd quarter. Atria Wealth Solutions Inc. now owns 20,566 shares of the medical equipment provider's stock valued at $2,312,000 after purchasing an additional 1,144 shares in the last quarter. International Assets Investment Management LLC boosted its stake in Zimmer Biomet by 11,244.9% during the 4th quarter. International Assets Investment Management LLC now owns 66,935 shares of the medical equipment provider's stock worth $8,146,000 after purchasing an additional 66,345 shares during the last quarter. Amalgamated Bank grew its holdings in shares of Zimmer Biomet by 3.0% during the third quarter. Amalgamated Bank now owns 56,166 shares of the medical equipment provider's stock worth $6,303,000 after buying an additional 1,631 shares in the last quarter. Finally, Sequoia Financial Advisors LLC raised its position in shares of Zimmer Biomet by 37.5% in the fourth quarter. Sequoia Financial Advisors LLC now owns 155,965 shares of the medical equipment provider's stock valued at $18,981,000 after buying an additional 42,539 shares during the last quarter. 88.89% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

ZBH has been the topic of several recent research reports. StockNews.com cut Zimmer Biomet from a "strong-buy" rating to a "buy" rating in a report on Monday, February 19th. Canaccord Genuity Group restated a "hold" rating and issued a $130.00 target price on shares of Zimmer Biomet in a report on Friday, February 23rd. Citigroup lifted their price target on Zimmer Biomet from $134.00 to $140.00 and gave the stock a "neutral" rating in a report on Wednesday, April 3rd. Evercore ISI increased their price target on shares of Zimmer Biomet from $125.00 to $130.00 and gave the company an "in-line" rating in a research note on Thursday, April 4th. Finally, Barclays lifted their price target on shares of Zimmer Biomet from $120.00 to $130.00 and gave the company an "underweight" rating in a research report on Monday, February 12th. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating and six have assigned a buy rating to the company's stock. Based on data from MarketBeat, the company presently has an average rating of "Hold" and a consensus target price of $133.29.

Zimmer Biomet Trading Down 0.9 %

Shares of ZBH stock traded down $1.05 on Friday, hitting $120.18. The stock had a trading volume of 1,185,820 shares, compared to its average volume of 1,311,871. The company's 50 day moving average price is $124.33 and its 200-day moving average price is $121.38. Zimmer Biomet Holdings, Inc. has a 1 year low of $102.00 and a 1 year high of $147.50. The company has a debt-to-equity ratio of 0.38, a current ratio of 1.66 and a quick ratio of 0.80. The firm has a market capitalization of $24.72 billion, a P/E ratio of 26.01, a P/E/G ratio of 2.17 and a beta of 1.03.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last announced its quarterly earnings data on Thursday, May 2nd. The medical equipment provider reported $1.94 earnings per share for the quarter, beating analysts' consensus estimates of $1.87 by $0.07. The firm had revenue of $1.89 billion during the quarter, compared to analysts' expectations of $1.87 billion. Zimmer Biomet had a net margin of 12.93% and a return on equity of 12.70%. The business's quarterly revenue was up 3.2% compared to the same quarter last year. During the same quarter in the previous year, the business posted $1.89 earnings per share. Analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8.1 earnings per share for the current year.

Zimmer Biomet Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, July 31st. Stockholders of record on Wednesday, June 26th will be paid a $0.24 dividend. This represents a $0.96 annualized dividend and a dividend yield of 0.80%. The ex-dividend date of this dividend is Wednesday, June 26th. Zimmer Biomet's payout ratio is currently 20.78%.

Insider Activity at Zimmer Biomet

In related news, VP Chad F. Phipps sold 26,156 shares of the company's stock in a transaction that occurred on Thursday, February 22nd. The shares were sold at an average price of $128.62, for a total transaction of $3,364,184.72. Following the sale, the vice president now directly owns 44,145 shares in the company, valued at $5,677,929.90. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. 0.95% of the stock is currently owned by company insiders.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.